Clinically, the high TGFB1 (tumour) and TGFBR2 (CD4+ T cells) expression were jointly associated with inferior survival in HBV+ DLBCL, highlighting their potential as complementary prognostic markers capturing tumour‐immune interactions, distincted from established clinical predictors such as IPI, cell‐of‐origin, and double‐hit status.55, 56. The gene discussed is TGFBR2; the disease is neoplasm.